Key facts
- This page summarizes Keli Walbert's Form 4 filing for Apellis Pharmaceuticals, Inc. (APLS).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 10 Jan 2025, 17:39.
Keli Walbert - 08 Jan 2025 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)
- Reporting relationship
- Director
- Issuer ticker
- APLS
- Reported as of
- 08 Jan 2025
- Net transaction value
- +$507,804
- SEC form
- 4
- Accepted by SEC
- 10 Jan 2025, 17:39:26 UTC
- Next SEC filing
- 15 Dec 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ David Watson, attorney-in-fact for Keli Walbert
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Keli Walbert filed Form 4 for Apellis Pharmaceuticals, Inc. (APLS) on 10 Jan 2025.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: +$507,804.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
APLS
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +9,090
- Change %
- Price
- $0.000000
- Shares after
- 9,090
- Date
- 08 Jan 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
APLS
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $507,804
- Shares
- +15,388
- Change %
- Price
- $33.00
- Shares after
- 15,388
- Date
- 08 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,388
- Exercise price
- $33.00
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
This restricted stock unit was granted on January 8, 2025. The restricted stock unit will fully vest on the first anniversary of the date of grant, subject to her continued service as a director, or upon later termination of her service as a director at her election.
Footnote F2
This represents a stock option award granted January 8, 2025 that vest 1/3rd per year over a three-year period subject to continued service.